About this trial
This study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. The study design is a single-arm prospective cohort observational study. Using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. The primary outcome is genetic variants of pancreatic cysts associated with malignancy. The secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.
Eligibility criteria
Qualifiers
Pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection
Patients who gave written informed consent
Disqualifiers
Anyone who has not signed a written consent form.
Patients deemed unsuitable for research (severe infection, drug abuse, severe mental illness, etc.)
Trial design
Treatments tested in this trial
- NA (No intervention)